Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in liver and viral disease drug candidates, reported a net loss of $24.2 million in 2025, significantly improved from $131.2 million in 2024. Operating income remained negative at approximately -$88 million, reflecting sustained R&D investments. The company held $77.8 million in cash, cash equivalents, and short-term investments at year-end 2025, providing runway into Q3 2026. Ongoing capital raises and collaborations are critical to continue operations amid increasing clinical development expenses. Growth prospects depend on successful clinical outcomes, regulatory milestones, and strategic partnerships.